Form 4: Avidity CMO Sells Shares in Novartis Merger

Avidity Biosciences' Chief Medical Officer disposed of all common stock and stock options following the company's acquisition by Novartis AG for $72.00 per share.

Summary

• Steven George Hughes, Chief Medical Officer of Avidity Biosciences, Inc. (RNAM), reported the disposal of 115,857 shares of Common Stock.
• The disposal also included various tranches of stock options, totaling 315,133 derivative securities, with exercise prices ranging from $6.57 to $31.42.
• These transactions are pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• The stock options were disposed of in exchange for a cash payment equal to the excess of the merger consideration of $72.00 per share over their respective exercise prices.
• Following these transactions, Steven George Hughes beneficially owns 0 shares of Common Stock and 0 derivative securities.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development for Avidity Biosciences shareholders, as the acquisition by Novartis AG at $72.00 per share represents a successful exit and a significant premium for their equity.

Positives

• The merger consideration of $72.00 per share represents a significant premium over the exercise prices of the disposed stock options, indicating a substantial gain for the option holder.
• The acquisition by Novartis AG provides a clear and profitable exit for Avidity Biosciences shareholders.

Future Outlook

This filing primarily reports a past/scheduled insider transaction related to a merger and does not provide forward-looking statements or guidance for Avidity Biosciences as an independent entity. The future outlook for the company's assets and operations will be integrated into Novartis AG's strategy.

Industry Context

StockSavvy.ai notes this acquisition reflects ongoing consolidation within the biotechnology sector, where larger pharmaceutical companies like Novartis AG are actively acquiring innovative smaller firms to bolster their pipelines and expand market presence. Such mergers often highlight the value placed on specialized therapeutic platforms and early-stage assets.

Comparison to Industry Standards

• This Form 4 filing reports an insider transaction related to a merger, rather than operational or financial performance, so direct comparison to industry-standard financial metrics or project results is not applicable.
• The acquisition price of $72.00 per share for Avidity Biosciences can be assessed against typical biotech acquisition multiples (e.g., revenue multiples, pipeline value), but the filing does not provide sufficient data for such a detailed comparative analysis.

Stakeholder Impact

• Shareholders: Benefit from the acquisition premium of $72.00 per share.
• Employees (specifically the reporting CMO): Realize gains from their equity holdings (common stock and options) as part of the merger.

Next Steps

• The completion of the merger and the integration of Avidity Biosciences into Novartis AG's operations.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Common Stock, Chief Medical Officer, Biotechnology, Pharmaceuticals